BACKGROUND AND OBJECTIVES: Albuminuria is associated with risk for renal and cardiovascular disease. It is difficult to predict which persons will progress in albuminuria. This study investigated whether assessment of urinary markers associated with damage to different parts of the nephron may help identify individuals that will progress in albuminuria. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Individuals were selected from a prospective community-based cohort study with serial follow-up and defined as "progressors" if they belonged to the quintile of participants with the most rapid annual increase in albuminuria, and reached an albuminuria ≥150 mg/d during follow-up. Patients with known renal disease or macroalbuminuria at baseline were excluded. Each progressor was matched to two control participants, based on baseline albuminuria, age, and sex. Furthermore, damage markers were measured in a separate set of healthy individuals. RESULTS: After a median follow-up of 8.6 years, 183 of 8394 participants met the criteria for progressive albuminuria. Baseline clinical characteristics were comparable between progressors and matched controls (n=366). Both had higher baseline albuminuria than the overall population. Urinary excretion of the glomerular damage marker IgG was significantly higher in progressors, whereas urinary excretion of proximal tubular damage markers and inflammatory markers was lower in these individuals compared with controls. Healthy individuals (n=109) had the lowest values for all urinary damage markers measured. CONCLUSIONS: These data suggest that albuminuria associated with markers of glomerular damage is more likely to progress, whereas albuminuria associated with markers of tubulointerstitial damage is more likely to remain stable.
BACKGROUND AND OBJECTIVES:Albuminuria is associated with risk for renal and cardiovascular disease. It is difficult to predict which persons will progress in albuminuria. This study investigated whether assessment of urinary markers associated with damage to different parts of the nephron may help identify individuals that will progress in albuminuria. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Individuals were selected from a prospective community-based cohort study with serial follow-up and defined as "progressors" if they belonged to the quintile of participants with the most rapid annual increase in albuminuria, and reached an albuminuria ≥150 mg/d during follow-up. Patients with known renal disease or macroalbuminuria at baseline were excluded. Each progressor was matched to two control participants, based on baseline albuminuria, age, and sex. Furthermore, damage markers were measured in a separate set of healthy individuals. RESULTS: After a median follow-up of 8.6 years, 183 of 8394 participants met the criteria for progressive albuminuria. Baseline clinical characteristics were comparable between progressors and matched controls (n=366). Both had higher baseline albuminuria than the overall population. Urinary excretion of the glomerular damage marker IgG was significantly higher in progressors, whereas urinary excretion of proximal tubular damage markers and inflammatory markers was lower in these individuals compared with controls. Healthy individuals (n=109) had the lowest values for all urinary damage markers measured. CONCLUSIONS: These data suggest that albuminuria associated with markers of glomerular damage is more likely to progress, whereas albuminuria associated with markers of tubulointerstitial damage is more likely to remain stable.
Authors: Hans L Hillege; Vaclav Fidler; Gilles F H Diercks; Wiek H van Gilst; Dick de Zeeuw; Dirk J van Veldhuisen; Rijk O B Gans; Wilbert M T Janssen; Diederick E Grobbee; Paul E de Jong Journal: Circulation Date: 2002-10-01 Impact factor: 29.690
Authors: Sara-Joan Pinto-Sietsma; Wilbert M T Janssen; Hans L Hillege; Gerjan Navis; Dick DE Zeeuw; Paul E DE Jong Journal: J Am Soc Nephrol Date: 2000-10 Impact factor: 10.121
Authors: Kristian Wachtell; Hans Ibsen; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Peter M Okin; Per Omvik; Suzanne Oparil; Hans Wedel; Steven M Snapinn; Peter Aurup Journal: Ann Intern Med Date: 2003-12-02 Impact factor: 25.391
Authors: Marit D Solbu; Ingrid Toft; Maja-Lisa Løchen; Ellisiv B Mathiesen; Bjørn O Eriksen; Toralf Melsom; Inger Njølstad; Tom Wilsgaard; Trond G Jenssen Journal: J Am Soc Nephrol Date: 2015-06-05 Impact factor: 10.121
Authors: A Lianne Messchendorp; Esther Meijer; Folkert W Visser; Gerwin E Engels; Peter Kappert; Monique Losekoot; Dorien J M Peters; Ron T Gansevoort Journal: Am J Nephrol Date: 2019-10-10 Impact factor: 3.754
Authors: A W S de Souza; W H Abdulahad; P Sosicka; J Bijzet; P C Limburg; C A Stegeman; M Bijl; J Westra; C G M Kallenberg Journal: Clin Exp Immunol Date: 2014-11 Impact factor: 4.330
Authors: Gdayllon Cavalcante Meneses; Alexandre Braga Libório; Elizabeth Francesco de Daher; Geraldo Bezerra da Silva; Marcus Felipe Bezerra da Costa; Maria Araci Andrade Pontes; Alice Maria Costa Martins Journal: BMC Infect Dis Date: 2014-08-20 Impact factor: 3.090
Authors: Moon Bae Ahn; Kyoung Soon Cho; Seul Ki Kim; Shin Hee Kim; Won Kyoung Cho; Min Ho Jung; Jin-Soon Suh; Byung-Kyu Suh Journal: Children (Basel) Date: 2021-05-19
Authors: A Lianne Messchendorp; Esther Meijer; Wendy E Boertien; Gerwin E Engels; Niek F Casteleijn; Edwin M Spithoven; Monique Losekoot; Johannes G M Burgerhof; Dorien J M Peters; Ron T Gansevoort Journal: Kidney Int Rep Date: 2017-10-14
Authors: Coen C W G Bongers; Mohammad Alsady; Tom Nijenhuis; Anouk D M Tulp; Thijs M H Eijsvogels; Peter M T Deen; Maria T E Hopman Journal: Physiol Rep Date: 2018-06